Key result
In patients with stable chronic heart failure, higher BMI significantly lowers NTproBNP levels, yet NTproBNP retains its prognostic power across all BMI groups.
Why the study?
Does obesity status (BMI) affect NT-proBNP levels and its prognostic power in patients with chronic stable heart failure?
Does obesity status (BMI) affect NT-proBNP levels and its prognostic power in patients with chronic stable heart failure?
In patients with stable heart failure, higher BMI is independently associated with lower NT-proBNP levels, but this does not diminish the biomarker's prognostic value.
NT-proBNP retains prognostic value across BMI groups in stable HF; supports risk stratification yet leaves optimal thresholds open.
Even matched for NYHA, age, sex, and renal function, BMI exerts a significant and independent inverse influence on NTproBNP in patients with stable CHF. NTproBNP retained equal statistical power in all three BMI groups.
No takes yet. Share an insight, caveat, or question.
Frankenstein et al. (2008) studied this question. In patients with stable chronic heart failure, higher BMI significantly lowers NTproBNP levels, yet NTproBNP retains its prognostic power across all BMI groups.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: